EyePoint Pharmaceuticals, Inc.EYPTNASDAQ
Loading
Year-over-year total asset growth rate
5Y CAGR
+18.1%/yr
Long-term compound
Percentile
P87
Within normal range
vs 5Y Ago
2.3x
Strong expansion
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 44.62% |
| Q3 2025 | -16.42% |
| Q2 2025 | -16.94% |
| Q1 2025 | -13.36% |
| Q4 2024 | 39.06% |
| Q3 2024 | -7.20% |
| Q2 2024 | -1.52% |
| Q1 2024 | -7.30% |
| Q4 2023 | 121.93% |
| Q3 2023 | -8.89% |
| Q2 2023 | 13.62% |
| Q1 2023 | -14.28% |
| Q4 2022 | -18.20% |
| Q3 2022 | -5.54% |
| Q2 2022 | -4.55% |
| Q1 2022 | -7.14% |
| Q4 2021 | 56.54% |
| Q3 2021 | -5.91% |
| Q2 2021 | -4.44% |
| Q1 2021 | 104.04% |
| Q4 2020 | 19.44% |
| Q3 2020 | 10.20% |
| Q2 2020 | -13.21% |
| Q1 2020 | 10.03% |
| Q4 2019 | -7.71% |
| Q3 2019 | -13.43% |
| Q2 2019 | 11.58% |
| Q1 2019 | 4.72% |
| Q4 2018 | -12.03% |
| Q3 2018 | 23.98% |
| Q2 2018 | 42.89% |
| Q1 2018 | 253.30% |
| Q4 2017 | 6.53% |
| Q3 2017 | -28.64% |
| Q2 2017 | 6.70% |
| Q1 2017 | -11.35% |
| Q4 2016 | -20.80% |
| Q3 2016 | -21.15% |
| Q2 2016 | -12.57% |
| Q1 2016 | 51.00% |